| Autor: |
Abdelaziz, N. A., Abdalla, T. M., Thabet, Y. A., Fawzy, S. M. |
| Předmět: |
|
| Zdroj: |
QJM: An International Journal of Medicine; 2020 Supplement, Vol. 113, pi187-i187, 1/3p |
| Abstrakt: |
Aim of the Work: This prospective analysis was planned for patients with chronic central serous retinopathy (CSR) more than three months who receive oral Eplerenone for treatment. It is aimed to reduce &resolve sub retinal fluid with improving anatomical and physiological visual functions. Patient &Methods: sixteen eyes with untreated chronic Central Serous Chorioretinopathy patients who recruited from the ophthalmic clinic. Main intervention is medication by standard dose of Eplerenone, 50mg once daily. Investigated by Optical Coherence Topography at base line, one month after treatment and three months later. Over the course of the study, patients were monitored for side effects, visual and anatomical response to themedication. Results: Significant difference in BCVA is found that was 0.675 ±0.2696 at base line to 0.48125±0.2287 after one month after treatment and to 0.04375±0.07274 three months after treatment, (p=0.000). Sub retinal fluidmeasurements were improved significantly between each two visits as horizontal fluid volume is improved from 2137±987.93 at base line to1559.875±677.60 after one month after treatment and to 0 three months after treatment. Vertical fluid volume is improved from 203.125±118.73 at base line to122±49.876 after one month after treatment and to 0 three months after treatment. Central sub field thickness were improved significantly between each two visits as it is improved from 372.375±92.994 at base line to331.8125±90.283 after one month after treatment and to 250.25±25.970 three months after treatment. Contrast sensitivity improved significantly between each two visits as it is improved from 8.7625±4.029 at base line to 5.1968±3.227 after one month after treatment and to 1.4968±0.4750 three months after treatment. Choroidal thickness was improved significantly between each two visits as it was improved from 267.9375±67.451 at base line to 222±52.262 after one month after treatment and to 174.0625±23.713 three months after treatment. 100% of the patients complained from positive scotoma at base line, Improved to 44% of the patients complained from positive scotoma one month after treatment, improved to 0% threemonths after treatment. Conclusion: Eplerenone therapy resulted in significant anatomic and visual improvements in eyes with chronic central serous Chorioretinopathy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
